An interventional study of Increased lifestyle walking (intervention) and Health education only (control) in Respiratory Impairment, Elevated Blood Pressure and Physical Inactivity, sponsored by Iowa State University. Enrolling by invitation at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2023-09-13.
Sponsored by Iowa State University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 349 studies in Respiratory Insufficiency with a site in United States — 44 open to participants now, 60 under way, 1 of them phase 3. Respiratory Insufficiency · United States.
Among the 349 studies in Respiratory Insufficiency with a site in United States, this one is the 147th largest by planned enrollment of the 253 interventional ones that give a count, is one of 20 that started in 2023, is one of 159 with no phase, reaches primary completion later than 3 of the 59 other live ones, and was the 306th registered.
1,371 studies on the registry are indexed under Respiratory Insufficiency; 266 are open to participants now.
Browse Respiratory Insufficiency studies →44 of the 349 studies in Respiratory Insufficiency with a site in United States are open now. Recruiting first, the newest first:
University of California, Davis · Sites in United States
Ages up to 28 days
University of Rochester · Sites in United States
Ages 18+ · Healthy volunteers
Thomas Jefferson University · Sites in United States
Ages 18+ · Healthy volunteers
Ohio State University · Sites in United States
Ages 18+
University of Wisconsin, Madison · Sites in United States
Ages 1 days–17 yrs
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.
This study: 65 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
349 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 31 · Phase 2 42 · Phase 3 27 · Phase 4 9
First in 1992; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 30 is below the median of 60 across 861 interventional studies indexed under Respiratory Insufficiency.
Median enrollment 42 across the 253 interventional studies, 65 across the 95 observational. Of the 246 that completed or were terminated, 93 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
47 of 349 have an industry lead sponsor. The 10 most frequent:
Iowa State University is the lead sponsor of 37 studies on the registry; 6 are open to participants now.
Iowa State University has 1 study filed under Respiratory Insufficiency — fewer than ten, so there is no comparison to draw.
24 of the studies in Respiratory Insufficiency with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07217197Thomas Jefferson UniversityRespiratory Monitoring System That Detects & Predicts OIRD | 2026-11-30 |
| NCT04664192Baylor Research InstituteBio-Banking of Specimens for Advanced Lung Disease and Lung Transplant Research | 2026-12-01 |
| NCT05462600University of California, San DiegoDistribution of Ventilation, Respiratory Drive and Gas Exchange: Measurements and Monitoring | 2026-12-30 |
| NCT05893420AgileMD, Inc.A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | 2026-12-31 |
| NCT06938217Institute for Extracorporeal Life SupportSafety and Efficacy of Low-Flow ECMO in a Multi-modal Cohort of Adults in Respiratory Failure | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 349 studies in Respiratory Insufficiency with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the effect of an 8-week walking program on blood pressure in inactive older adults with respiratory impairment, a condition where lung function is sub-optimal for a person's age. Older adults with respiratory impairment have greater risks of death by cardiovascular disease (CVD) compared to those without respiratory impairment, and this may be partly driven by higher resting blood pressure. One way to lower blood pressure is to increase the number of daily steps achieved throughout the course of everyday life ('lifestyle steps'), and previous research shows that an additional 3,000 lifestyle steps/day is effective for achieving this. However, whether an increase in daily lifestyle steps is effective for reducing blood pressure in senior-community dwelling older adults with respiratory impairment is unknown. Understanding how increasing daily steps impacts blood pressure in this understudied population is important for informing future strategies for tackling cardiovascular disease risk in those with lung dysfunction.
Older adults are particularly susceptible to respiratory impairment (a condition of lung dysfunction) due in part to longer lifetime exposures to air pollutants, tobacco smoke, and physical inactivity. Older adults with respiratory impairment have greater long-term risks of death by cardiovascular disease (CVD) when compared to individuals without respiratory impairment. Impaired lung function tends to run parallel with high blood pressure, and high blood pressure is a determinant of CVD mortality in this population. One approach to lowering blood pressure across the lifespan is by increasing physical activity (PA) behavior. Walking is the most commonly practiced modality of PA in older adulthood, and previous studies show that accumulating an additional 3,000 steps/day over 5-days a week through activities of daily living (i.e., 'lifestyle stepping') reduces blood pressure in inactive older adults free from respiratory impairment. This step-based PA prescription roughly equates to 150-minutes of moderate-intensity aerobic PA/week for most inactive older adults, and therefore satisfies the minimum aerobic PA recommendations for substantial health benefits. However, the impact of such an intervention on blood pressure in older adults with respiratory impairment is unclear. The 'Physical Activity Guidelines for Americans: Midcourse Report' (2023) indicates that senior centers are key settings for successful PA interventions. Senior-living communities are traditionally well-designed and well-resourced to support PA (e.g., safe outdoor walking spaces; access to indoor exercise facilities; social support, etc.), making them highly suitable locations for lifestyle walking. Additionally, the prescription of PA using lifestyle step counts rather than time-based prescriptions is intuitive and arguably easier to integrate into activities of daily living. However, no study has yet evaluated the effect of increasing daily lifestyle step counts on blood pressure in older adults with respiratory impairment. Addressing this gap in knowledge will provide support for the utility of lifestyle walking as a therapeutic approach to CVD risk management in older adults with lung dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Intentional increase in daily steps: 3,000 extra steps/day, 5-days a week, 8-weeks total.
Other: Increased lifestyle walking (intervention)
Health education and no intentional increase in baseline daily steps (but with the option to receive the intervention upon conclusion of the initial 8-weeks).
Other: Health education only (control)
Participants will increase their baseline steps by a minimum of 3,000 extra steps/day, 5-days/week, for 8-weeks. Baseline steps will be assessed using a pedometer over a 7-day period before the intervention, after which a new (higher) daily step target will be assigned. The intervention will take place in the free-living setting, with participants reaching their step goals by engaging in more activities of daily living or via purposeful physical activity. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants will be supported in their efforts to meet their daily step targets by engaging in once-weekly walking groups (30-mins/session) led by research staff. They will also receive 20-minute phone calls once every two weeks to set goals and create action plans for reaching their step targets.
Those randomized to the delayed participation group will be instructed to maintain their 'normal' lifestyle activities, thereby avoiding any significant increase in daily step counts beyond their 'baseline' values. Participants will wear a pedometer throughout the 8-week period to keep track of their steps, and adherence to the protocol will be determined by collecting the stored step data directly from each participant's pedometer on a weekly basis. Participants in this group will attend once-weekly group health education sessions (30-minutes/session), in addition to 5-minute, 'touch base' phone calls once every 2-weeks, but these phone calls will not involve goal-setting or action planning. After completing the initial 8-week period, these individuals can then opt to undertake the 'increased lifestyle walking' intervention of 3,000 extra steps/day over 5-days for 8-weeks if desired.
Change in systolic blood pressure
Pre- and post-intervention brachial blood pressure (upper left arm) will be assessed after 10-minutes of quiet rest in the supine position using the SphygmoCor device (AtCor Medical, Itasca, IL, USA), an automated blood pressure monitor. The participant will be free of constrictive clothing, their legs will be uncrossed, and their back will be supported by a cushioned surface (i.e., bed) beneath them. A minimum of 3 blood pressure measurements will be taken at intervals of at least 2 minutes.
Time frame: 0-weeks, 8-weeks
Feasibility of conducting the study
The secondary purpose of this pilot study is to explore two (2) facets of feasibility: adherence and attrition, with the study considered to be feasible if 'high adherence' and 'low attrition' are observed. High adherence is defined as all participants meeting their daily step goals 80% of the time (i.e., 32 days out of a possible 40 days). Low attrition is defined as 80% or more participants attending both pre- and post-intervention assessments.
Time frame: 8-weeks
Change in arterial stiffness
Pre- and post-intervention arterial stiffness will be estimated through the assessment of carotid-femoral pulse wave velocity using the SphygmoCor device (AtCor Medical, Itasca, IL, USA) immediately following the resting blood pressure assessment. The participant will lie down and a blood pressure cuff will be placed around the upper leg and a pressure sensor will be applied to the carotid artery to obtain femoral and carotid pulse waves. The distance between the femoral and carotid pulses will be measured with a tape measure and the pulse transit time between the two locations will be calculated by the SphygmoCor device (AtCor Medical, Itasca, IL, USA).
Time frame: 0-weeks, 8-weeks
Change in lung function
Pre- and post-intervention lung function will be assessed by spirometry using a handheld spirometer (EasyOne Air, NDD Medical Technologies, Andover, MA), specifically performing the Forced Vital Capacity (FVC) maneuver. The participant begins by inhaling air to maximum lung volume without the device in their mouth, and then forcefully exhaling through the device until the lungs are completely emptied. A minimum of 3 and a maximum of 8 FVC maneuvers will be will be performed following the American Thoracic Society guidelines, and the device will use inbuilt algorithms to measure the forced expiratory time. The primary indices of lung function will include the Forced Vital Capacity (FVC), the Forced Expiratory Volume in 1-second (FEV1), and the ratio between the two (FEV1/FVC).
Time frame: 0-weeks, 8-weeks
Change in SPPB performance
Pre- and post-intervention assessment of lower extremity functioning consists of a usual-paced walking test (i.e., normal gait speed) over a flat 4m course; a series of two-footed balance poses each lasting 10 seconds: feet side-by-side, feet partially staggered \[semi-tandem\], and feet in the heel-to-toe position \[fully tandem\]; and five unaided chair stands completed as quickly as possible.
Time frame: 0-weeks, 8-weeks
Change in functional capacity
Pre- and post-intervention functional capacity will be evaluated using the fast 400m walk test, a validated measure of walking ability and endurance designed specifically for older adults. Participants will walk at a fast pace around two cones set 20m apart in a long hallway on level ground for 10 full laps (i.e., 400m), and the time taken to complete the test (mins:secs) will be recorded (faster times equate to better functional capacity). Participants will be provided with verbal encouragement throughout to test to maximize the effort exerted.
Time frame: 0-weeks, 8-weeks
Change in exertional dyspnea (breathlessness)
Pre- and post-intervention exertional dyspnea (the perception of breathlessness experienced during exercise) will be assessed using a validated 10-level severity scale (modified Borg index) where 0 = no shortness of breath and 10 = maximum shortness of breath. The Borg index will be administered immediately following completion of the functional capacity test (i.e., fast 400m walk).
Time frame: 0-weeks, 8-weeks
Change in sleep quality
Pre- and post-intervention sleep quality will be evaluated using the validated Pittsburgh Sleep Quality Index (PSQI).
Time frame: 0-weeks, 8-weeks
Change in quality of life
Pre- and post-intervention quality of life will be evaluated using the validated 36-item short form survey (SF-36).
Time frame: 0-weeks, 8-weeks
Change in respiratory symptoms
Pre- and post-intervention respiratory symptoms will be evaluated using the validated St. George's Respiratory Questionnaire (SGRQ).
Time frame: 0-weeks, 8-weeks
Change in fatigability
Pre- and post-intervention physical and mental fatigability will be evaluated using the validated Pittsburgh Fatigability Scale. This is a 10-item questionnaire that evaluates self-reported whole-body physical and mental tiredness anchored to activities of fixed intensity and duration in adults age ≥60 years. Each item in the scale ranges from 0 to 5, where 0 represents "no fatigue whatsoever" and 5 represents "extreme fatigue." The scores from each item are then summed to give a total score between 0 and 50. A higher score reflects greater fatigability.
Time frame: 0-weeks, 8-weeks
Change in cognitive performance
Pre- and post intervention cognitive performance will be evaluated using the validated modified mini-mental state examination (3MS).
Time frame: 0-weeks, 8-weeks
Change in waist circumference
Pre- and post intervention waist circumference (measured in cm) will be evaluated using a digital measuring tape (Smart Tape Measure V001, Fitindex, Eastvale, CA).
Time frame: 0-weeks, 8-weeks
Plan to share: Yes — De-identified, individual participant data may be shared with researchers outside of the institution upon submission of a pre-analysis plan and, if required by federal regulations, approval from the institutional review board (IRB).
Supporting information: Study protocol
Time frame: Data will become available for sharing from January 2024 onward, and pre-analysis plans can be submitted indefinitely thereafter.
Access criteria: There are no data-sharing agreements in place at this time. However, the study has IRB support to share data in a manner that maintains the confidentiality of participants, honors assurances made to participants during informed consent, and complies with data privacy regulations. Researchers wishing to affiliate with the project must first pass a course on the Protection of Human Subjects, and data requests will be conveyed to the institutional review board (IRB) (if required). The IRB will determine the nature of the request and later provide recommendations. Approval will be based on a pre-submitted analysis plan from the researchers. Upon approval, an agreement between the PI and the researchers will be made, and de-identified data will be cut from the main dataset and distributed electronically. The researchers will agree to publish only the results of the analysis plan, and must seek further assent if significant deviations from this plan are made.
No publications or documents are linked to this record.
Start is estimated for Sep 2023; primary completion for Jan 2024, 4 months later.
Of 360 non-industry interventional studies with no phase under Respiratory Insufficiency, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 47. This study's planned 4 months is below that.
Counting every sponsor, half of 376 studies reached it within 24 months; a quarter within 10 and three quarters within 46.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Iowa State University